Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2024
0mins
Source: Globenewswire
Company Presentation Announcement: Passage Bio, Inc. will have its CEO, Will Chou, present at Chardan’s 8th Annual Genetic Medicines Conference on October 1, 2024, with a live webcast available for viewers.
Focus on Neurodegenerative Diseases: Passage Bio is dedicated to developing one-time genetic therapies for neurodegenerative diseases, particularly through their lead candidate PBFT02, aimed at treating frontotemporal dementia by enhancing progranulin levels.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
